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Abstract
Background and Objectives While evidence in support of
aspirin use in secondary prevention is well documented, the
role of aspirin in primary prevention remains unclear. We
conducted a systematic literature review to evaluate aspirin use
in cardiovascular disease (CVD) and cancer primary preven-
tion, and consider whether aspirin’s role is set to become more
clearly defined based on past and prospective studies.
Data Sources Utilizing PubMed, the reviewers identified
appropriate Medical Subject Headings (MeSH) terms to
establish CVD-based studies, cancer-based studies, and
studies on adherence.
Study Eligibility Criteria Date restrictions of May 31,
2008 to May 31, 2013 were applied to capture the most
robust meta-analyses and randomized controlled trials.
Websites of relevant EU and US scientific societies were
used to identify the key guidelines for aspirin use in pri-
mary prevention of CVD, and ClinicalTrials.gov was used
to establish future or ongoing trials.
Results Evidence in support of aspirin prophylaxis is con-
flicting, though some meta-analyses have underlined poten-
tial benefit in reducing cardiovascular events. Despite this
apparent benefit, bleeding risk with aspirin is consistently
higher versus control, and remains a concern. A reduction of
cancer incidence and mortality after a least 3 and 5 years
treatment, respectively, is also apparent with aspirin.
Conclusion Available data on aspirin in primary pre-
vention suggest a modest benefit for patients at high risk of
CVD, and a promising benefit for those at risk of cancer.
Future studies should help to elucidate whether the benefit
of aspirin outweighs risk in appropriate patient groups.
Key Points
Aspirin appears to provide a somewhat modest
benefit in primary prevention of cardiovascular
disease; more well-defined patient groups to
establish those who would benefit most from regular
aspirin are required.
Data from post hoc analyses of aspirin use in primary
prevention of cancer are promising, especially in
colorectal cancer; however, the extent of aspirin
benefit in a high-burden disease requires further
investigation in randomized controlled trials.
All authors participated as paid consultants in a roundtable meeting
on the use of aspirin in primary prevention, sponsored by Bayer
HealthCare.
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1 Introduction
Both cardiovascular disease (CVD) and cancer are leading
causes of mortality worldwide. In 2008, of the 57 million
deaths that occurred globally, 36 million of these—almost
two-thirds—were due to non-communicable diseases
(NCDs), of which CVD and cancer were responsible for 17
million (47 % of all NCD deaths) and 7.6 million (21 % of
all NCD deaths), respectively [1].
Low-dose aspirin has been used for many years in the
treatment and prevention of CVD. While the clinical ben-
efits of aspirin for secondary prevention are well estab-
lished, evidence on the role of aspirin for primary
prevention is less clear. Current guidelines on the pro-
phylactic use of aspirin vary widely, sometimes with
conflicting recommendations. This may be due to varying
interpretations of data from clinical trials of aspirin in
primary prevention, which lead to differences in the per-
ceived risk–benefit profile for aspirin.
Perception of the benefit versus risk ratio of aspirin for
primary prevention may be influenced by the increasing
body of evidence that aspirin reduces the risk of colorectal
cancer (CRC) and other cancers [2, 3]. Recently revised
guidelines on the management of Lynch syndrome (LS),
which is the major, hereditary form of CRC, recommend
the use of aspirin on the basis of long-term (i.e., 10 years)
follow-up data from the CAPP2 trial, where aspirin sig-
nificantly reduced the incidence of CRC in LS carriers [4].
As the overall benefit versus risk ratio is not yet clear,
this paper systematically reviews the clinical evidence on
the use of aspirin in primary prevention for CVD (with or
without diabetes) and cancer. Moreover, it explores current
use of aspirin in clinical practice and the clinical implica-
tions should subjects not adhere to their prophylactic reg-
imen. Subsequent to these findings, we explore whether it
is time for a new approach to the prophylactic use of
aspirin by the most appropriate patient groups and make
recommendations of our own while we await further out-
come data from ongoing trials.
2 Methods
We conducted a systematic literature review, utilizing the
PubMed database, to identify randomized controlled trials
(RCTs) and meta-analyses of aspirin in the primary pre-
vention of CVD (in subjects with and without diabetes) and
cancer. We also investigated the impact of non-adherence
and discontinuation of aspirin use once prescribed for
primary prevention, and searched the websites of relevant
EU and US scientific societies to identify the key guide-
lines for aspirin use in primary prevention of CVD.
2.1 Literature Searches and Data Extraction
The systematic review was conducted following the
PRISMA guidelines. The search criteria can be observed in
Table 1. The following search criteria to establish CVD-
based studies on patients with or without diabetes were
included: (clinical trial or meta-analysis), aspirin, primary
prevention, and CVD. For the cancer search criteria, the
following search terms were used: aspirin, cancer, and
(meta-analysis or clinical trial). For all searches, the search
was limited to human studies, English language was used,
and date restrictions May 31, 2008 to May 31, 2013 were
applied to allow for a 5-year assessment of the evidence base.
In order to be included, the meta-analyses had to (1)
provide information on prophylactic aspirin use in relation
to CVD or cancer incidence; and/or (2) have cancer in
general or CRC incidence or mortality as an endpoint; (3)
report original data and include hazard ratios (HRs), odds
ratios (ORs), or relative risks (RRs) and their 95 % confi-
dence intervals (CIs); and (4) synthesize data from RCTs
that compared aspirin therapy with placebo/vitamins in
adults [18 years old with no history of CVD, or
adults [18 years without cancer, though meta-analyses of
observational and cohort studies were considered if they
addressed point 1 of the criteria. Indeed, cancer is often
studied observationally. Exclusion criteria for the meta-
analyses included studies that were considered to be short
term (less than 1 year of follow-up), and studies that were
not published as full reports, such as conference abstracts
and letters to editors. In addition, individual articles that
were not of RCTs were excluded from this systematic
review as cohort and case–control studies have limitations
in the study design, which reduced the quality of the data
obtained. Full text review was performed, and all authors
determined the quality of articles. Risk of bias was con-
sidered and minimized by our chosen selection criteria.
For the search relating adherence to aspirin, the following
search criteria were used: aspirin, primary prevention, CVD,
and (prevalence or patient medication knowledge or patient
adherence or medication adherence/persistence). Because of
the low number of relevant publications retrieved, we ana-
lyzed all relevant studies that provided information on
aspirin use in primary prevention, and therefore included
cohort studies and cross-sectional studies. Additional pub-
lications identified in pertinent review articles were also
reviewed. We understand the merit and limitations of these
studies, and provide a narrative summation to help form our
future hypotheses in the conclusions.
2.2 Data Synthesis
A narrative review of all extracted articles was undertaken;
data reported from retrieved articles were either
114 C. Brotons et al.
summarized or tabulated. The limitations for each study
were considered and documented accordingly (e.g., publi-
cations bias and heterogeneity).
3 Results
3.1 Aspirin Use in the Prevention of Cardiovascular
Disease
3.1.1 Cardiovascular (CV) Events
The search terms yielded 31 publications, of which nine
were appropriate meta-analyses [5–13]. Ten primary
studies are included in the meta-analyses, though only one
of these was identified in our own search because of the
publication date restrictions. The Early Treatment Diabetic
Retinopathy Study (ETDRS) was included in three of the
meta-analyses, though prevention of CVD was not the
purpose of the study [14]. The nine trials that investigated
aspirin for the primary prevention of cardiovascular (CV)
events are listed in Table 2 [15–23]. Four additional sub-
group or post hoc analyses for these trials were identified in
our literature search, and are analyzed in the context of
their original studies [24–27]. The meta-analyses and trials
focused on patients with diabetes are described in a later
section [9–13, 15, 19, 27].
The reasons for exclusion of the other 18 articles were
varied; however, the most common reasons were review
article (n = 4 articles), use of aspirin as a polypill (n = 2),
use of aspirin in other indications (n = 3), and study of
determinants of aspirin use (n = 2). The primary analysis
of one retrieved meta-analysis [28] pooled data from pri-
mary and secondary prevention trials and was therefore
excluded. No meta-analyses of observational studies of
aspirin for primary CVD prevention were retrieved by the
search terms. Inspection of one of the review articles
obtained in the search [29] identified an additional relevant
meta-analysis [30].
Details of the meta-analyses included are shown in
Table 3 [5–13, 30]. The meta-analyses report reductions in
CV events with aspirin treatment compared with non-
aspirin treatment; however, the differences are significant
in only a small number of cases (Table 4) [5–13, 30]. For
example, a 12 % proportional reduction in serious vascular
events [myocardial infarction (MI), stroke, or vascular
death] was reported in Baigent et al. [5] (aspirin 0.51 % vs.
control 0.57 % per year; p = 0.0001), which was largely
due to a 23 % RR reduction for non-fatal MI (aspirin
0.18 % vs. control 0.23 % per year; p \ 0.0001) (Table 2).
The meta-analysis by de Berardis et al. [10] also explored
sex-specific differences; aspirin significantly reduced the
risk of MI among men by 43 % [three trials: Primary
Prevention Project (PPP), ETDRS, and Physicians’ Health
Study (PHS); 3,126 participants; 265 events; RR 0.57
(95 % CI 0.34–0.94); p = 0.03]. Conversely, no effect of
aspirin was observed among women [three studies:
Women’s Health Study (WHS), PPP, ETDRS; 3,176 par-
ticipants; 245 events; RR 1.08 (95 % CI 0.71–1.65);
p = 0.71]. In men, aspirin use was not associated with a
reduced risk of stroke compared with placebo or no treat-
ment [two trials: PPP and WHS; 2,593 participants; 93
events; RR 1.11 (95 % CI 0.75–1.64); p = 0.61], while in
women, a risk reduction was observed [three studies: WHS,
PPP, ETDRS; 3,176 participants; 127 events; RR 0.75
(95 % CI 0.37–1.53); p = 0.43], albeit deemed not sig-
nificant. Of note, Berger et al. [31] investigated the sex-
specific differences in these outcomes in a previous meta-
analysis; these findings influenced guideline development
and are discussed later in the review.
There was no evidence that aspirin significantly reduces
CV mortality in the five meta-analyses that did not focus on
patients with diabetes (Table 4). A similar effect was seen
for all-cause mortality, although in one meta-analysis, the
Table 1 Search criteria for systematic review
Search strategy Number of articles
retrieved
Included Excluded
Clinical trial[Publication Type] OR meta-analysis[Publication Type] AND ‘‘aspirin’’[MeSH
Terms] AND ‘‘primary prevention’’[MeSH Terms] AND ‘‘cardiovascular diseases’’[MeSH
Terms] AND ‘‘humans’’[MeSH Terms] AND English[Language] AND ‘‘2008/05/31’’[PDAT]:
‘‘2013/05/31’’[PDAT]
31 13 18
((‘‘aspirin’’[MeSH Terms] AND ‘‘neoplasms’’[MeSH Terms]) AND ((‘‘meta-analysis’’[Publication
Type] OR ‘‘meta-analysis as topic’’[MeSH Terms] OR ‘‘meta-analysis’’[All Fields]) OR clinical
trial[Publication Type])) AND (‘‘2008/05/31’’[PDAT]: ‘‘2013/05/31’’[PDAT]) AND ((‘‘2008/05/
31’’[PDAT]: ‘‘2013/05/31’’[PDAT]) AND ‘‘humans’’[MeSH Terms] AND English[lang])
80 6 74
(((Aspirin[MeSH] AND primary prevention[MeSH] AND cardiovascular disease[MeSH] AND
(Prevalence[MeSH] OR Patient Medication Knowledge[MeSH] OR Patient Adherence[MESH]
OR Medication Adherence[MeSH] OR Medication Persistence[MeSH])))) AND (‘‘2008/05/
31’’[Date—Publication]: ‘‘2013/05/31’’[Date—Publication])
13 3 10





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Aspirin in Primary Prevention 117
reduction in patients receiving aspirin was of borderline
significance [RR 0.94 (95 % CI 0.88–1.00); p = 0.05] [7].
In the WHS, the primary endpoint (major CV events)
was not reduced significantly with aspirin use [RR 0.91
(95 % CI 0.80–1.03); p = 0.13], though risk of all-cause
stroke and ischemic stroke were significantly reduced [RR
0.83 (95 % CI 0.69–0.99), p = 0.04, and RR 0.76 (95 %
CI 0.63–0.93), p = 0.009, respectively] [21]. A post hoc
analysis of this study, utilizing existing risk scores and an
‘optimal fit’ model to predict treatment effects for indi-
vidual women in terms of absolute risk reduction for major
CV events with aspirin concluded that aspirin appeared to
be ineffective in the majority of females, but that selective
treatment of women C65 years of age was of positive net
benefit if the 10-year number-willing-to-treat (NWT)
individuals was [50, but not if the NWT was B50 [24].
Since almost all women \65 years of age (99.2 %)
had B2 % predicted absolute treatment effect, the authors
of this study concluded that the place for aspirin in primary
prevention in women is limited, with age being the stron-
gest determinant of treatment effect. A separate subanalysis
of the WHS aimed to explore the role of aspirin in CVD
prevention in subjects with migraine; aspirin had similar
protective effects on ischemic stroke for women with or
without migraine [26]. By contrast, women with migraine
with aura on aspirin had increased risk of MI. Authors
acknowledge that this result should be cautiously
interpreted.
In the primary RCT focusing on patients with hyper-
tension [Hypertension Optimal Treatment study (HOT)],
aspirin significantly reduced major CV events [RR 0.85
(95 % CI 0.73–0.99); p = 0.03], particularly MI [RR 0.64
(95 % CI 0.49–0.85); p = 0.002], though did not affect the
overall incidence of stroke [RR 0.98 (95 % CI 0.78–1.24);
p = 0.88] [18]. In a post hoc subgroup analysis of this
study, it was concluded that the benefit of aspirin is
amplified in patients with hypertension and chronic kidney
disease, with progressive (but non-linear) increases in
aspirin benefit for major CV events, MI, all-cause stroke,
CV mortality, and total mortality with decreasing renal
function [25]. Aspirin was associated with pronounced,
statistically significant reductions in the endpoints of CV
mortality, all-cause stroke, and all-cause mortality in
patients with an estimated glomerular filtration rate (GFR)
of B 45 ml/min/1.73 m2. These findings indicate a greater
benefit of aspirin in patients with reduced GFR, which is
likely attributable to these patients being at higher CV risk.
3.1.2 Bleeding Events
Of the six meta-analyses focusing on data from non-dia-
betes patients (Table 4), bleeding events were analyzed in









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Aspirin in Primary Prevention 121
risk of major extracranial bleeding with aspirin [RR 1.54
(95 % CI 1.30–1.82); p \ 0.0001], which was greater
(non-significant) in patients with higher cholesterol. The
excess risk of bleeds was mostly non-fatal. Perhaps by
chance, fatal gastrointestinal (GI) or other fatal extracranial
bleeds were lower in the aspirin group versus control [9 vs.
20; RR 0.48 (95 % CI 0.17–1.34)] [5]. Of the other four
meta-analyses, one reported significant increases in hem-
orrhagic stroke [RR 1.36 (95 % CI 1.01–1.82); p = 0.04],
major bleeding [RR 1.66 (95 % CI 1.41–1.95);
p \ 0.00001], and GI bleeding [RR 1.37 (95 % CI
1.15–1.62); p = 0.0003] [7], while another reported com-
parable increases in hemorrhagic stroke and major bleeding
[16]. The meta-analysis by Seshasai et al. [8] reported a
70 % excess risk in total bleeds and 30 % of non-trivial
bleeds (Table 4). One did not report pooled data for
bleeding events [6].
3.2 Prophylactic Use of Aspirin for Prevention of CV
Events in Patients With Diabetes
3.2.1 CV Events
Table 4 shows the main CV outcomes from five meta-
analyses that focused on data from patients with diabetes.
None of these analyses reported a significant protective
effect of aspirin for prevention of CV events [9–13]. All of
the point estimates for the major CV and mortality-related
outcomes in these meta-analyses favored aspirin, and in the
meta-analysis of Butalia et al. [9], the reduction in major
adverse cardiac events (MACE) was of borderline signifi-
cance (p = 0.05) (Table 4). No significant protective effect
of aspirin has been observed in patients with diabetes,
according to findings from the Japanese Primary Preven-
tion of Atherosclerosis with Aspirin for Diabetes (JPAD)
and Prevention of Progression of Arterial Disease and
Diabetes (POPADAD) trials [15, 19]. In a subanalysis of
the JPAD trial, in patients with diabetes, the outcomes of
patients with hypertension were compared with those of
normotensive patients [27]. While the incidence of cere-
brovascular events was higher in patients with hypertension
relative to those without [HR 2.84 (95 % CI 1.52–5.52);
p = 0.0008], use of aspirin reduced the incidence rate in
patients with hypertension to a similar level to that in
patients without hypertension [HR 1.64 (95 % CI
0.83–3.29); p = 0.15]. However, aspirin use did not sig-
nificantly decrease the incidence of cerebrovascular events
in the group of patients with hypertension [27].
3.2.2 Bleeding Events
The meta-analyses that focused on patients with diabetes
also reported incidence of bleeding events (Table 2).
Stavrakis et al. [11] reported a statistically significant
increased risk of major bleeding with aspirin using a fixed-
effect pooled estimate [RR 2.51 (95 % CI 1.11–5.70);
p = 0.028]; however, the difference was no longer signifi-
cant using a random-effects pooled estimate [RR 3.02
(95 % CI 0.48–18.86); p = 0.24]. Although the other meta-
analyses reported numerically higher incidences of a range
of bleeding categories with aspirin in patients with diabetes,
none of these increases was statistically significant [9, 10,
12, 13]. This included the category of GI bleeding, for
which a non-significant RR of 2.1 was reported in three of
the meta-analyses [9–11]. Indeed, considering the bleeding
risk in the two individual RCTs in patients with diabetes, in
the POPADAD trial, the incidence of GI bleeding was not
significantly increased in patients receiving aspirin [OR
0.90 (95 % CI 0.53–1.52); p = 0.69] [15]. In the JPAD
trial, there was no significant difference in the composite of
hemorrhagic stroke and severe GI bleeding between
patients in the aspirin and non-aspirin groups, based on 17
such events that occurred during the study [19].
3.3 Prophylactic use of Aspirin in Colorectal Cancer
The search terms retrieved 80 articles, of which six were
relevant meta-analyses (Table 4) [32–37]. Two additional
meta-analyses evaluated data on aspirin for the prevention
of colorectal adenoma, but these publications were not
analyzed further because they were secondary prevention
trials [38, 39]. Of the additional articles that were excluded,
the most common reasons for exclusion were study on
aspirin/non-steroidal anti-inflammatory drugs in other types
of cancer (n = 28 articles), (pharmaco)genetic study
(n = 5), and review article (n = 3). One article reported a
systematic comparison of evidence from observational
studies versus randomized trials [40]; however, there was
no clear statement that the non-randomized studies included
were primary prevention studies, and pooled data on the
randomized trials in this article are already included in the
meta-analysis by Rothwell et al. [34], which is included in
Table 5. Five of the retrieved articles were RCTs [41–44].
3.3.1 Incidence
In a pooled analysis of six trials of daily low-dose aspirin
for the primary prevention of CV events, during a follow-
up period of 4–8 years, overall cancer incidence was
reduced by 19 % [OR 0.81 (95 % CI 0.67–0.98); p = 0.03]
after 3–4.9 years of aspirin use, increasing to 29 %
at C5 years of use [OR 0.71 (95 % CI 0.57–0.89);
p = 0.003], independent of age, sex, and smoking status
[34]. In a related meta-analysis of five UK trials, a pro-
tective effect of aspirin against the development of new
cancer was accompanied by a significant reduction in the

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































124 C. Brotons et al.
incidence of cancer with distant metastasis [HR 0.64 (95 %
CI 0.48–0.84); p = 0.001], with a significant benefit for
adenocarcinomas, but not for other solid cancers [33].
Additional meta-analyses of observational and epidemio-
logical studies provide supporting evidence for the protec-
tive effect of aspirin against cancer [35, 37]. In a meta-
analysis of observational studies (case–control and cohort
studies), there was a 27 % reduction in the risk of CRC with
regular aspirin use [RR 0.73 (95 % CI 0.73–0.79);
p \ 0.001]; in terms of duration of aspirin use, the RR was
0.80 (95 % CI 0.71–0.91) for \5 years and 0.75 (95 % CI
0.70–0.80) for C5 years (P for heterogeneity = 0.369)
[35]. Overall, risk reductions were stronger in case–control
studies versus cohort studies, corresponding with a signifi-
cant heterogeneity observed (p \ 0.001). The authors
believed the high variability of aspirin use definitions across
studies may partly explain the heterogeneity observed in
risk estimates across studies. Moreover, this meta-analysis
included case–control studies, which might be subject to
selection and recall bias, leading to heterogeneous results.
Publication bias was also significant. Despite the publica-
tion bias reported, a consistent cancer risk reduction was
apparent, supporting the causality of this association.
In order to elucidate the public health implication of
aspirin use in cancer prevention, the dose–risk and dura-
tion–risk relationships were assessed by Ye et al. [37] in a
separate meta-analysis. Based on their findings, Ye et al.
[37] concluded that the threshold effect is a dose of
75–325 mg daily and 2–7 times per week; there was a non-
linear relation between dose of aspirin use and CRC risk
(P for non-linearity = 0.020). According to a random
effects cubic spline model, there was stronger risk reduc-
tion for higher aspirin dose [RR 0.80 (95 % CI 0.74–0.88)
for 325 mg per day, and RR 0.74 (95 % CI 0.65–0.83) for
650 mg per day]. This model, which included all studies on
frequency of aspirin use (times per week), also indicated a
non-linear relation between CRC risk and frequency of
aspirin use (P for non-linearity = 0.007). Notably, there
was a stronger risk reduction for people taking aspirin
7 times a week [RR 0.82 (95 % CI 0.78–0.87)] compared
with twice per week [0.92 (95 % CI 0.88–0.95)]; this
benefit was not strengthened in people taking aspirin more
than 7 times a week [RR 0.82 (95 % CI 0.78–0.87) for 10
times per week] [37]. This meta-analysis included cohort
studies only, with no evidence of heterogeneity observed
across these studies.
3.3.2 Mortality
In a meta-analysis of eight trials including 25,570 patients,
aspirin use significantly reduced the overall incidence of
cancer-related death by 21 % [32]. When the analysis was
confined to the three trials with long-term follow-up
(C5 years), a reduction in cancer mortality with aspirin
was observed for all solid cancers [OR 0.80 (95 % CI
0.72–0.88); p \ 0.0001] and GI cancers [OR 0.65 (95 %
CI 0.54–0.78); p \ 0.0001], but not hematological cancers
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Fig. 1 Effect of allocation to aspirin versus control on the 20-year
risk of death due to the most common fatal cancers in 10,502 patients
with scheduled treatment duration of C5 years in three trials with
long-term follow-up. Figure originally published in Rothwell et al.
[32]. Reproduced with permission. Data are from a pooled analysis of
three long-term follow-up trials [20, 23, 45]. All were randomized
trials, during which patients received daily aspirin (75–1,200 mg) for
*4 to 6.8 years (mean follow-up). Long-term data for deaths due to
cancer following completion of the trials were collected via the
national death certification and cancer registration systems
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32, 45]. There was a significant effect of aspirin on the
20-year risk of death from CRC [OR 0.60 (95 % CI
0.45–0.81); p = 0.0007], with a reduction in death evident
from about 10 years onward. For deaths due to other can-
cers, such as esophageal or lung cancer, the benefit of
aspirin was observed from 5 years onwards. In the meta-
analysis of six trials of low-dose aspirin for primary pre-
vention of CV events, cancer deaths were significantly
reduced by 37 % from 5 years onwards [OR 0.63 (95 % CI
0.47–0.86); p = 0.004] [34]. In a further meta-analysis,
aspirin also significantly reduced overall cancer mortality
[RR 0.77 (95 % CI 0.63–0.95); p = 0.019] [36].
3.3.3 Bleeding Events
Of the included cancer-related meta-analyses, only one
included results for adverse events attributable to aspirin
use. In the meta-analysis of six trials, an increased risk of
extracranial bleeding was observed with low-dose aspirin;
however, the analysis of extracranial bleeding stratified by
period of follow-up revealed that the risk of extracranial
bleeding decreases over time, becoming comparable to that
of placebo or no aspirin from 3 years onwards: \3 years,
OR 1.95 (95 % CI 1.47–2.59); 3–4.9 years, 1.37
(0.87–2.14); C5 years, 0.63 (0.34–1.16) (p = 0.003 for
interaction) [34]. In this same analysis, fewer cases of fatal
bleeding were associated with aspirin use, compared with
controls [8/203 vs. 15/132, respectively; OR 0.32 (95 % CI
0.12–0.83); p = 0.009] [34].
3.4 Aspirin Utilization
Our search string for this topic identified 13 publications,
of which only three publications were deemed relevant.
In a cross-sectional study of aspirin use in Wisconsin,
USA, for primary prevention (with data from the Survey of
the Health of Wisconsin), only 31 % of the 268 participants
(aged 35–74 years) for whom aspirin was indicated,
according to United States Preventive Services Task Force
(USPSTF) guidelines, were using it regularly (defined
as C4 times per week) [46]. Among these participants with
an aspirin indication, older patients and women had a
significantly higher likelihood of regular aspirin intake
compared with younger participants and men (OR 1.07,
p \ 0.001, and 3.49, p = 0.021, respectively) [46]. In a
retrospective, cross-sectional cohort study in community
outpatients in Italy, only 15.2 % of 151,526 patients free
from CVD received an aspirin prescription for primary
prevention, despite being eligible for regular aspirin use
according to the official guidelines stipulated by the Italian
Medicine Agency. Indeed, patients with either type 2 dia-
betes and age [40 years or without type 2 diabetes but
aged C55 years (men) or C65 years (women) with at least
one risk factor (obesity, dyslipaemia, smoking cigarettes,
hypertension, family history of CVD) were considered
eligible [47]. A study conducted in the USA between 2005
and 2007 showed that the prevalence of regular aspirin
(C3 days per week) use for primary prevention was only
31 and 44 % for the 3,431 individuals at increased and high
risk of coronary heart disease (CHD), respectively, with
important racial and ethnic disparities [48].
3.5 Aspirin Adherence
Data on adherence to aspirin therapy for primary preven-
tion of CV events are relatively scant. Indeed, the authors
of a 2012 meta-analysis of studies that assessed patient
adherence to CV preventive treatment for either primary or
secondary prevention reported that no trials reporting
adherence to aspirin therapy for primary prevention were
identified [49].
A post hoc analysis of the WHS (study detailed in
Table 2) [21] used statistical models to estimate the effect
of continuous aspirin treatment on CV events [50].
Whereas the intent-to-treat population had small but non-
significant reductions in total CV events [RR 0.91 (95 %
CI 0.81–1.03); p = 0.13] and CV mortality [RR 0.95
(95 % CI 0.74–1.22); p = 0.68], adjustment for aspirin
non-compliance strengthened the effect of aspirin on CVD
mortality, albeit without statistical significance [RR 0.76
(95 % CI 0.54–1.08); p = 0.13].
3.6 What Do the Guidelines Say?
A summary of current guidelines for aspirin use in primary
prevention is provided in Table 6 [51–55]. The majority of
existing guidelines are based on meta-analyses and sys-
tematic reviews of the nine clinical trials for aspirin in
primary prevention. The assessment and interpretation of
these data can vary, leading to different outcomes for
overall aspirin risk–benefit. Because of their basis on the
nine aspirin primary prevention of CVD trials, most
guidelines {European Society of Cardiology (ESC) [52],
USPSTF [55], American Heart Association/American
Stroke Association (AHA/ASA) [54], American Diabetes
Association (ADA) [51]} only consider the benefits of a
reduction in CV risk versus potential harms from bleeding.
However, recommendations from different guideline bod-
ies are sometimes conflicting. For example, the ESC 2012
guidelines state that aspirin cannot be recommended for
primary prevention in patients without overt CVD, because
of the increased risk of major bleeding (although it is
recommended for some special patient groups, i.e.,
hypertensive patients without a history of CVD, patients
with reduced renal function, and those at high CV risk)
[52]. In contrast, the American College of Chest Physicians
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(ACCP) 2012 guidelines suggest daily low-dose aspirin
(75–100 mg) in people aged C50 years without symp-
tomatic CVD [53]. The latter recommendations are based
on an evaluation of the preventive benefit of aspirin on both
CVD and cancer. The remaining guidelines cited in
Table 6 recommend, in one way or another, the use of
aspirin in specific groups of patients in primary prevention.
Both the USPSTF [55] and AHA/ASA [54] guidelines
have specific recommendations for men and women. The
USPTF guidelines recommend aspirin for men age
45–79 years when the potential benefit due to a reduction
in MI outweighs the potential harm, while aspirin is only
recommended for women age 55–79 years when the
potential benefit of a reduction in ischemic strokes out-
weighs the potential harm. AHA guidelines also specifi-
cally recommend against aspirin use in men for stroke
prevention, while stating that aspirin can be useful in
women whose risk of stroke is sufficiently high enough for
the benefits to outweigh the harms of treatment. When
considering patients with diabetes, both ADA and AHA
recommend aspirin therapy (75–162 mg/day) for primary
prevention of heart disease for people with diabetes
aged [40 years or who have additional risk factors for
CVD and no contraindications to aspirin therapy [51, 54].
Currently, only the ACCP guidelines also mention data
showing a reduction in cancer risk with aspirin [53].
4 Discussion
4.1 CV Benefits
Recent meta-analyses provide evidence of a modest benefit
for aspirin in primary CV prevention, with a number of
studies reporting statistically significant reductions in
serious CV events, which did not extend to a reduction in
CV or all-cause mortality across these studies [5–7]. The
lack of statistical significance for outcomes related to
mortality in some of these analyses might be attributed to
the fact that the majority of patients included in these
studies were not at high risk of CVD.
Although CV benefit was not observed in patients with
diabetes enrolled in primary prevention trials, it has been
suggested that these trials were not adequately powered to
attain a reliable answer [56]. Indeed, in the JPAD trial, the
investigators predicted 52 primary CV events per 1,000
person-years, but the actual rate was only 17 events per
1,000 person-years, therefore reducing the statistical rele-
vance. Another possible explanation for the poor level of
prevention afforded by aspirin in this patient population
could be a reduced efficacy of low-dose aspirin in sup-
pressing platelet function. It is hypothesized that faster
resynthesis of platelets in patients with diabetes and
thereby a faster resynthesis of megakaryocyte/platelet
Table 6 Overview of current guidelines on the use of aspirin in primary prevention
Organization Recommendation
European Society of Cardiology (ESC) [52] In patients without overt CVD, aspirin cannot be recommended in primary prevention
because of increased risk of major bleeding
Antiplatelet therapy may be considered in hypertensive patients without a history of CVD,
but with reduced renal function or at high CV risk
Antiplatelet therapy with aspirin is not recommended for people with diabetes who do not
have clinical evidence of atherosclerotic disease
American Diabetes Association (ADA) [51] Consider aspirin therapy (75–162 mg/day) as a primary prevention strategy in those with
type 1 or type 2 diabetes at increased CV risk (10-year risk [10 %). This includes most
men aged [50 years or women aged [60 years who have at least one additional major risk
factor (family history of CVD), hypertension, smoking, dyslipidemia, or albuminuria
American College of Chest Physicians (ACCP)
[53]
Persons aged C50 years without symptomatic CVD: low-dose aspirin 75–100 mg daily
American Heart Association/American Stroke
Association (AHA/ASA) [54]
Use of aspirin CV prophylaxis is recommended for persons whose risk is sufficiently high
for the benefits to outweigh the risks associated with treatment (i.e., 10-year risk of CV
event = 6–10 %)
Aspirin can be useful for the prevention of a first stroke among women whose risk is
sufficiently high for the benefits to outweigh the risks associated with treatment
Aspirin is not useful for preventing a first stroke in persons at low risk
Aspirin is not useful for preventing a first stroke in persons with diabetes or diabetes plus
asymptomatic peripheral artery disease in the absence of any other CVD
United States Preventive Services Task Force
(USPSTF) [55]
Encourage men aged 45–79 years to use aspirin when the potential benefit of a reduction in
MI outweighs the potential harm
Encourage women aged 55–79 years to use aspirin when the potential benefit of a reduction
of ischemic stroke outweighs the potential harm
CVD cardiovascular disease, CV cardiovascular, MI myocardial infarction
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cyclooxygenase (COX) isozymes may allow sufficient
recovery of COX-1 activity during the 24-h dosing interval
(particularly between 12–24 h), to overcome the anti-
platelet effect of aspirin [57, 58]. Evidence from human
pharmacokinetic studies suggests that twice-daily admin-
istration of low-dose aspirin in patients with diabetes
reverses this pattern of insufficient COX-1 activity inhibi-
tion seen with a single daily aspirin dose [58]; however,
trials with a clinical outcome parameter are required to
confirm these preliminary findings. Another approach
might be to increase the aspirin dose in resistant patients
with diabetes. Results from a recent subanalysis of the
Aspirin Versus/Or Clopidogrel in Aspirin-resistant Dia-
betics inflammation Outcomes (AVOCADO) trial showed
that doubling the aspirin dose from 75 mg to 150 mg once
daily improved platelet reactivity suppression in patients
with type 2 diabetes and high platelet reactivity versus
aspirin 75 mg once daily [59].
4.2 Cancer Benefit
Evidence from primary RCTs demonstrate a reduction in
the incidence of CRC and mortality from CRC with daily
aspirin therapy [32–34, 36, 60]. In the meta-analysis by
Rothwell et al. [32], aspirin reduced mortality by about
20 %. The reduction in cancer-related mortality observed
was consistent across trials, despite the different popula-
tions included in the trials. Furthermore, the benefit of
aspirin seems to be limited to certain cancers, with the most
apparent benefit observed in adenocarcinomas, and by the
length of treatment. Indeed, aspirin was only found to
reduce cancer incidence from 3 years onwards [324 vs. 421
cases; OR 0.76 (95 % CI 0.66–0.88); p = 0.0003], and
benefit of aspirin on reducing cancer mortality was only
apparent from 5 years onwards of treatment [66 vs. 104
deaths; OR 0.63 (95 % CI 0.47–0.86); p = 0.004] [34]. Of
note, as a reduced cancer mortality is not observed in
people treated with warfarin, which has a similar bleeding
profile to aspirin, it is unlikely that diagnostic procedures
carried out early on in the investigations due to unexpected
bleeding were the reason for lower cancer mortality [32].
Unlike the meta-analysis of RCTs observing no dose-
response effect on cancer outcomes [32], the meta-analysis
of cohort studies by Ye et al. [37] reported an inverse
relationship between CRC incidence and aspirin dose and
aspirin frequency [37], with a 75- to 325-mg daily dose 2–7
times per week considered to provide optimal benefit. In
the same analyses, there was also suggestion that longer-
term ([5 years) use of aspirin is necessary in order to
demonstrate a protective effect on cancer risk [37], which
is concordant with conclusions drawn by Rothwell et al.
[32, 33] and consistent with ‘true’ prevention of the dis-
ease. On the topic of duration of aspirin exposure, a more
clear cancer benefit in women has been observed with
aspirin use lasting for 10 or more years, such as in the
82,911 women in the Nurses’ Health Study [61]. The
benefit observed in this study appears to be dose dependent,
with a trend (p \ 0.001 for trend) in benefit observed by
number of aspirin taken in a week [risk reduction in women
taking aspirin [14 times a week 0.68 (95 % CI
0.49–0.95)]. Moreover, women who took more than 14
aspirin a week, 10 years preceding the study, had an even
lower RR of 0.47 (95 % CI 0.31–0.71). That said, the
incidence of major GI bleeding was also dose related,
which again highlights the consideration required when
determining the optimal dose of aspirin for benefit to
supersede risk.
Similarly, and more recently, during the development of
our review article, an update of the WHS on alternate-day
aspirin use and cancer incidence, which was outside the
time points given in our search criteria, was published [62].
Understanding of the apparent lag time before cancer
benefit is observed; the WHS aimed to decipher whether
alternate-day, low-dose aspirin use for 10 years [median
active treatment of 10.3 years (range 8.2–10.9)] is associ-
ated with reduced risk of CRC in a post-treatment follow-
up period (median follow-up of up to 18 years) [62]. A
total of 33,682 women agreed to continue participation,
with slightly more women in the aspirin arm compared
with the placebo arm [16,913 (89.1 %) vs. 16,769
(88.2 %); p = 0.006]. Unlike the original WHS [21] not
showing clear CRC benefits during the active 10-year
treatment phase, a post-treatment benefit in incidence of
CRC was observed. Indeed, cancer incidence was lower in
those taking aspirin [HR 0.80 (95 % CI 0.67–0.97);
p = 0.021] than placebo, primarily due to a reduction in
proximal colon cancer [HR 0.73 (95 % CI 0.55–0.95);
p = 0.022], with the effect emerging after 10 years. The
post-trial reduction in CRC was 42 % [HR 0.58 (95 %
CI = 0.42–0.80); p \ 0.001] [62]. Women who used
aspirin during the active treatment phase but did not use
aspirin post-trial had a 33 % lower rate of CRC [HR 0.67
(95 % CI 0.43–1.02)], while those who continued with
aspirin use had a 43 % lower rate of CRC [HR 0.57 (95 %
CI 0.35–0.93)].
Understanding that the effects of aspirin are not apparent
until at least 3 years after starting aspirin treatment, a
couple of studies have aimed to estimate the overall ben-
efits and harms of aspirin over a 5- or 10-year period. A
review of aspirin in cancer prevention conducted a 5-year
risk analysis of the combined vascular and major bleeding
events obtained from the ATT analysis of the six primary
prevention trials (primary prevention trials of aspirin ver-
sus placebo) with a hypothetical 10 % reduction in cancer
incidence by age and sex. This analysis showed a net
benefit of aspirin use for both men and women, with an
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even greater benefit for men aged C65 years, compared
with women or subjects of a younger age [3]. It is impor-
tant to note, the authors’ calculations of benefits after
5 years of use were based on an assumed reduction in
overall cancer incidence with aspirin and not on empirical
data. This may underestimate the reduction in cancer
incidence that would occur with continued aspirin use
beyond 10 years. A separate review that was published
during the development of this article aimed to explore the
‘best estimates’ for individuals taking aspirin for 10 years
by synthesizing data from available evidence on cancer,
CVD (data obtained from ATT analysis) and its harm, and
modeled these effects using general population data from
the UK [63]. For individuals taking aspirin for 10 years,
Cuzick et al. [63] estimated a ‘relative’ reduction of *9 %
in the number of men and 7 % in the number women with a
cancer, MI or stroke event over a 15-year period. Absolute
reductions (conservative estimate) ranged from 0.68 to
3.09 % in men and women; reductions in cancer incidence
were estimated to account for 61–80 % of the overall
benefit, with reductions in CRC accounting for 30–36 % of
it. Major bleeding events increased by between 0.16 and
0.81 % from baseline rates of 0.57–2.37 % over a 15-year
period. Based on these harms, the net relative benefit was
calculated to be about 6 %. Relative reductions in cancer
mortality were greater than that calculated for incidence
(4 % relative reduction all deaths); concordant with trial
data, no net reduction in CV-related deaths was reported.
The relative benefit for mortality was more profound in
men than in women, because of the lower baseline death
rate from these diseases. Overall, these analyses suggest a
net benefit for a minimum of 5 years of aspirin use, which
heightens with 10 years of use in both men and women
ranging between ages 50 and 65.
So what renders aspirin seemingly cancer protective?
The mechanism of action of aspirin in cancer prevention is
not yet fully understood. Although the inflammatory-rela-
ted gene COX-2 has been found to be over-expressed in
adenomas, the protective effect of low-dose aspirin has
been found to predominate in patients whose COX-2
expression was initially low [64]. Indeed, the main char-
acteristics of the chemopreventive effect of low-dose
aspirin are not consistent with either a direct inhibitory
effect on COX-2 or with a COX-independent mechanism
of action. Instead, it is hypothesized that aspirin may
reduce the metastatic spread by acting through platelet-
mediated mechanisms; indeed, permanent inactivation of
platelet COX-1 may play a key role in preventing colo-
rectal adenoma formation, by suppressing the induction of
COX-2 expression in adjacent cells [3, 65]. Aspirin may
also have a role in directing modulation of oncogene-
induced expression of transcription factors and promotion
of tumor cell apoptosis [66].
4.3 Establishing the Benefit Versus Bleeding Risk
The meta-analyses and randomized trial evidence demon-
strate the increased risk of bleeding with aspirin is
unequivocal, with most reporting a consistently high
bleeding risk profile with aspirin use compared with con-
trol. However, data regarding the influence of age, under-
lying comorbidities (e.g., uncontrolled hypertension), and
duration of use and dose of aspirin on bleeding risk are
limited and conflicting.
Previous reviews of the literature have cited that
increasing age per se should not be considered a significant
risk factor for bleeding induced by low-dose aspirin [67];
rather, older patients in general have a much greater
absolute risk of GI complications (GICs) than their younger
counterparts [67], because there is a sharp increase in
baseline risk of upper GICs (UGICs) in general among
individuals aged C70 years [68]. Moreover, evidence
shows that rates of UGICs are higher in subjects with non-
complicated or complicated ulcers, compared with those
without GI symptoms, and bleeding risk increases with age,
irrespective of type of ulcer [68]. Notwithstanding, deaths
from GI bleeding attributable to aspirin appear not to be
increased [34]. Another aspect that should be considered is
the possibility of concomitant Helicobacter pylori infection
influencing bleeding risk. Evidence addressing the role of
H. pylori and bleeding risk is currently conflicting [69, 70].
Future studies (discussed in the next section) should help to
qualify whether determining H. pylori status, in addition to
age, sex and history of bleeds, is an important step towards
profiling the right patient, with the least risk of bleeding,
prior to commencement of aspirin prophylaxis.
4.4 Limitations
There exist some differences in trial design and patient
characteristics among the RCTs that explored aspirin in
CVD primary prevention; indeed, the primary endpoints
and treatment regimens (e.g., aspirin once-daily vs. every
other day) differed across each of the RCTs. Subsequent to
these differences, when these RCTs were analyzed in the
meta-analyses discussed in our review, statistical hetero-
geneity was reported among some of the efficacy and
safety outcomes. Notably, when Butalia et al. [9] from their
analyses of seven RCTs removed PHS and WHS, being the
largest of the trials, heterogeneity substantially decreased.
Thus, these meta-analyses have taught us that appropriately
sized trials, with more specific patient segregation designed
to consider different CVD risk profiles, are warranted to aid
more definitive conclusions on the patient group that would
likely benefit from aspirin in primary prevention of CVD.
Moreover, when considering the cancer benefit with
aspirin use, although promising findings have been
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observed in meta-analyses of RCTs [32–34, 36, 60], a
limitation of these analyses is that they are derived from
studies analyzing aspirin in CVD protection where cancer
was in most (with exception of WHS) not the primary
outcome. In addition, we place caution on findings
retrieved from a meta-analysis of observational studies; we
need to consider the limitations inherent to observational
studies, related in particular to measurement errors in the
exposure to aspirin and the variability of aspirin use.
Regarding limitations of our own review, despite hav-
ing rigorously reviewed the eligible articles extracted
utilizing the specific search strings given in Table 1, we
limited our search to the PubMed database, and restricted
the search between two particular time points (between the
years 2008 and 2013). However, we are confident of
aspirin in primary prevention being well catalogued
between these time points, and that the key articles of
interest have been reviewed here. During the preparation
of our manuscript, a robust systematic review by Sutcliffe
et al. [71] re-evaluated aspirin use in primary prevention
by estimating event rates, performing modeling on specific
outcomes (i.e., all-cause mortality) and estimated hetero-
geneity in order to further rationalize the benefit of aspirin
use according to the much scrutinized existing evidence
base. Beyond analyzing the current data, our objective was
to also review the evidence on studies on adherence of
aspirin and on the recommendations of international
guidelines, as well as presenting a hypothesis on the future
direction of aspirin in primary prevention in anticipation
of prospective and ongoing trials that may shed greater
light on this subject.
4.5 Future Direction and Study Needs
A net benefit of aspirin that outweighs the risk of bleeding
has been demonstrated when considering reductions in CV
events and cancer together [34], thus one can speculate that
aspirin may have a greater role in the primary prevention of
both of these diseases in the near future. As such, it has
been suggested that CRC benefits should be incorporated
into CHD risk scores in order to determine the benefit-to-
risk ratio for aspirin use [72].
To identify those patients for whom aspirin is most
appropriate, it is of our opinion a new individual approach
to assessment that considers the combined benefits of
aspirin as well as bleeding risk is required. Future criteria
that might define a subject eligible for primary prevention
with aspirin may include:
• Healthy subjects with a significantly increased risk of
CVD using available risk charts.
• Healthy subjects with a significantly increased risk of
cancer, in particular, CRC.
• Healthy subjects with a combined moderate risk of both
CVD and cancer.
The ASPREE trial, an ongoing randomized, double-
blind study in the USA and Australia (expected to be
completed by December 2018), should provide further
evidence as to whether the benefits of daily aspirin use in
healthy, elderly people outweigh the risks. The study is
recruiting 19,000 healthy individuals aged over 70 years
who will receive 100 mg of aspirin or placebo daily for
5 years. The composite primary endpoint termed ‘disabil-
ity-free life’ includes onset of dementia, total mortality, or
persistent disability in at least one of the Katz Activities of
Daily Living, and the secondary endpoints [all-cause spe-
cific mortality, fatal and non-fatal CV events, fatal and
non-fatal cancer (excluding non-melanoma skin cancer),
dementia, mild cognitive impairment, depression, physical
disability, and clinically significant bleeding] will be
compared. The results of this large trial should provide
further insight into the risks versus overall benefits of
aspirin prophylaxis. However, we note that any trial with
short follow-up could potentially miss the net benefit,
especially of fatal and non-fatal cancer. Indeed, aspirin for
cancer prevention has a long lag time before benefits are
observed, while conversely the harms appear in the early
part of the treatment, particularly in those above 70 years
of age.
To resolve some of the uncertainties around aspirin use
in patients with diabetes, the results of ongoing clinical
trials of aspirin in patients with diabetes, such as the
Aspirin and Simvastatin Combination for CV Events Pre-
vention Trial in Diabetes (ACCEPT-D; International
Standard Randomized Controlled Trial Number:
48110081) and A Study of Cardiovascular Events iN
Diabetes (ASCEND; ClinicalTrials.gov identifier:
NCT00135226), are keenly awaited. Notably, these trials
are more powered to assess the efficacy in reducing CV
events than the past investigative trials discussed in our
review, and should shed better light on the role aspirin
plays in this clinical scenario.
Strategies to improve the bleeding profile of aspirin are
recommended for appropriate patients. For example, co-
administration of aspirin with a gastroprotective drug, such
as proton pump inhibitors, should be considered for
patients at high risk of UGICs, as these can lead to non-
adherence and discontinuation with aspirin therapy [73].
While there are conflicting data on the role of H. pylori as a
risk factor for UGICs with low-dose aspirin [69, 70], the
ongoing large-scale outcomes study Helicobacter Eradica-
tion Aspirin Trial (HEAT; ClinicalTrials.gov identifier
NCT01506986) promises to provide more definitive
information on the relationship between H. pylori infection
and GI bleeding during aspirin use. However, the limitation
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of this trial is that it investigates current users of aspirin and
does not account for the proportion of individuals who
discontinue aspirin because of GI symptoms.
Aspirin is currently underutilized in primary prevention
[47]. The full extent, reasons, and consequences of aspirin
underuse is poorly understood; reasons for underutilization
may be related to the patient, condition, therapy or
healthcare system. The highest-risk patients are frequently
older with cognitive or physical impairments, or multiple
comorbidities requiring polypharmacy. They may also hold
negative perceptions about aspirin bleeding risk or have a
low motivation to take indefinite therapy.
Since ‘healthy’ individuals are asymptomatic from a CV
viewpoint, and the benefits of aspirin for primary preven-
tion are not visible, while adverse events are obvious,
counseling is important and should include discussion of
the benefits of prophylaxis with patients prior to starting
aspirin use. Adherence should be monitored and effective
strategies to encourage therapeutic adherence employed.
There is also a need for greater public education on aspirin
for primary prevention, including information on the risks
of inappropriate aspirin use and the consequences of dis-
continuation [47].
5 Conclusions
Emerging data from prospective studies of the protective
effect of aspirin on cancer, combined with its proven effect
on reduction of CV events, are likely to be included in
future evaluations of benefit versus risk conducted by
guideline bodies. This may influence recommendations on
the use of aspirin for primary prevention, not only for CV
events, but also cancer. Since CVD and cancer share a
number of common risk factors, including a sedentary
lifestyle, obesity, diabetes, poor diet, and smoking [74],
and also share some disease mechanisms, a combined
approach to prevention would be logical. However, unlike
CVD risk assessment, there is some difficulty in assessing
cancer risk (except for cases with familial and genetic
factors) in clinical practice. Thus, profiling a patient who
would benefit from aspirin in primary prevention of cancer
should be based on their risk of bleeding rather the risk
factors for cancer.
Acknowledgments The authors would like to thank Professors
Carlo Patrono, He´ctor Bueno, and Peter Elwood for their invaluable
contribution to discussions at the roundtable meeting held in Paris,
France, December 2012. This meeting was funded by Bayer
HealthCare. Editorial assistance was provided by Victoria Panagakis
of Fishawack Communications Ltd and funded by Bayer HealthCare.
Conflicts of interest Dr Carlos Brotons is a member of the Exec-
utive Committee for the ARRIVE trial, which is sponsored by Bayer
HealthCare. Professor Limmroth has received honoraria as a speaker
or consultant from Allergan, Bayer HealthCare, BiogenIdec, Bristol-
Myers Squibb, Novartis, Pfizer, Roche, Merck Serono, and Teva. All
authors participated as paid consultants in a roundtable meeting on the
use of aspirin in primary prevention, sponsored by Bayer HealthCare.
The authors declare that there are no other conflicts of interest, that
they have full control of the primary data, and that they agree to allow
the journal to review the data if requested.
Role of the funding source The contents of the review article
entirely reflect the opinion of the authors. Carlos Brotons selected the
search criteria and determined the methodology. All authors reviewed
the literature and were each involved in the preparation of the man-
uscript. All authors critically reviewed the manuscript and approved
the final content. For the initial meeting of the authors (a roundtable
discussion), Bayer provided an unrestricted educational grant.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. World Health Organization. NCD mortality and morbidity. http://
www.who.int/gho/ncd/mortality_morbidity/en. Accessed 12 Mar
2014.
2. Rothwell PM. Aspirin in prevention of sporadic colorectal can-
cer: current clinical evidence and overall balance of risks and
benefits. Recent Results Cancer Res. 2013;191:121–42.
3. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer
prevention. Nat Rev Clin Oncol. 2012;9:259–67.
4. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for
the clinical management of Lynch syndrome (HNPCC): recom-
mendations by a group of European experts. Gut. 2013;62:812–23.
5. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary
and secondary prevention of vascular disease: collaborative meta-
analysis of individual participant data from randomised trials.
Lancet. 2009;373:1849–60.
6. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple
primary prevention trials of cardiovascular events using aspirin.
Am J Cardiol. 2011;107:1796–801.
7. Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on
mortality in the primary prevention of cardiovascular disease. Am
J Med. 2011;124:621–9.
8. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of
aspirin on vascular and nonvascular outcomes: meta-analysis of
randomized controlled trials. Arch Intern Med. 2012;172:209–16.
9. Butalia S, Leung A, Ghali W, et al. Aspirin effect on the inci-
dence of major adverse cardiovascular events in patients with
diabetes mellitus: a systematic review and meta-analysis. Car-
diovasc Diabetol. 2011;10:25.
10. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary
prevention of cardiovascular events in people with diabetes: meta-
analysis of randomised controlled trials. BMJ. 2009;339:b4531.
11. Stavrakis S, Stoner JA, Azar M, et al. Low-dose aspirin for pri-
mary prevention of cardiovascular events in patients with dia-
betes: a meta-analysis. Am J Med Sci. 2011;341:1–9.
12. Younis N, Williams S, Ammori B, et al. Role of aspirin in the
primary prevention of cardiovascular disease in diabetes mellitus:
a meta-analysis. Expert Opin Pharmacother. 2010;11:1459–66.
13. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of
cardiovascular events in patients with diabetes: a meta-analysis.
Diabetes Res Clin Pract. 2010;87:211–8.
Aspirin in Primary Prevention 131
14. Kassoff A, Buzney SM, McMeel J, et al. Aspirin effects on
mortality and morbidity in patients with diabetes mellitus: Early
Treatment Diabetic Retinopathy Study report 14. JAMA.
1992;268:1292–300.
15. Belch J, MacCuish A, Campbell I, et al. The Prevention Of
Progression of Arterial Disease And Diabetes (POPADAD) trial:
factorial randomised placebo controlled trial of aspirin and anti-
oxidants in patients with diabetes and asymptomatic peripheral
arterial disease. BMJ. 2008;337:a1840.
16. de Gaetano G. Low-dose aspirin and vitamin E in people at
cardiovascular risk: a randomised trial in general practice. Col-
laborative Group of the Primary Prevention Project. Lancet.
2001;357:89–95.
17. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of
cardiovascular events in a general population screened for a low
ankle brachial index: a randomized controlled trial. JAMA.
2010;303:841–8.
18. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive
blood-pressure lowering and low-dose aspirin in patients with
hypertension: principal results of the Hypertension Optimal
Treatment (HOT) randomised trial. HOT Study Group. Lancet.
1998;351:1755–62.
19. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for
primary prevention of atherosclerotic events in patients with type
2 diabetes: a randomized controlled trial. JAMA. 2008;300:
2134–41.
20. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic
daily aspirin in British male doctors. Br Med J (Clin Res Ed).
1988;296:313–6.
21. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-
dose aspirin in the primary prevention of cardiovascular disease
in women. N Engl J Med. 2005;352:1293–304.
22. Steering Committee of the Physicians’ Health Study Research
Group. Final report on the aspirin component of the ongoing
Physicians’ Health Study. Steering Committee of the Physicians’
Health Study Research Group. N Engl J Med. 1989;321:129–35.
23. The Medical Research Council’s General Practice Research
Framework. Thrombosis Prevention Trial: randomised trial of
low-intensity oral anticoagulation with warfarin and low-dose
aspirin in the primary prevention of ischaemic heart disease in
men at increased risk. The Medical Research Council’s General
Practice Research Framework. Lancet. 1998;351:233–41.
24. Dorresteijn JAN, Visseren FLJ, Ridker PM, et al. Aspirin for
primary prevention of vascular events in women: individualized
prediction of treatment effects. Eur Heart J. 2011;32:2962–9.
25. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial
in hypertensive patients with chronic kidney disease: a post-hoc
subgroup analysis of a randomized controlled trial. J Am Coll
Cardiol. 2010;56:956–65.
26. Kurth T, Diener HC, Buring JE. Migraine and cardiovascular
disease in women and the role of aspirin: subgroup analyses in
the Women’s Health Study. Cephalalgia. 2011;31:1106–15.
27. Soejima H, Ogawa H, Morimoto T, et al. Aspirin reduces cere-
brovascular events in type 2 diabetic patients with poorly con-
trolled blood pressure. Subanalysis from the JPAD trial. Circ J.
2012;76:1526–32.
28. Simpson SH, Gamble JM, Mereu L, et al. Effects of aspirin dose
on mortality and cardiovascular events in people with diabetes: a
meta-analysis. J Gen Intern Med. 2011;26:1336–44.
29. Tagliabue L, Dipaola F, Perego F, et al. Aspirin for the primary
prevention of cardiovascular diseases. Intern Emerg Med.
2012;7:375–9.
30. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of
cardiovascular events in patients without clinical cardiovascular
disease: a meta-analysis of randomized trials. Am Heart J.
2011;162(115–24):e2.
31. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the
primary prevention of cardiovascular events in women and men:
a sex-specific meta-analysis of randomized controlled trials.
JAMA. 2006;295:306–13 (Erratum in: JAMA. 2006;295:2002).
32. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin
on long-term risk of death due to cancer: analysis of individual
patient data from randomised trials. Lancet. 2011;377:31–41.
33. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on
risk of cancer metastasis: a study of incident cancers during
randomised controlled trials. Lancet. 2012;379:1591–601.
34. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of
daily aspirin on cancer incidence, mortality, and non-vascular
death: analysis of the time course of risks and benefits in 51
randomised controlled trials. Lancet. 2012;379:1602–12.
35. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a
quantitative review to 2011. Ann Oncol. 2012;23:1403–15.
36. Mills EJ, Wu P, Alberton M, et al. Low-dose aspirin and cancer
mortality: a meta-analysis of randomized trials. Am J Med.
2012;125:560–7.
37. Ye X, Fu J, Yang Y, et al. Dose-risk and duration-risk relation-
ships between aspirin and colorectal cancer: a meta-analysis of
published cohort studies. PLoS One. 2013;8:e57578.
38. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemopre-
vention of colorectal adenomas: meta-analysis of the randomized
trials. J Natl Cancer Inst. 2009;101:256–66.
39. Gao F, Liao C, Liu L, et al. The effect of aspirin in the recurrence
of colorectal adenomas: a meta-analysis of randomized controlled
trials. Colorectal Dis. 2009;11:893–901.
40. Algra AM, Rothwell PM. Effects of regular aspirin on long-term
cancer incidence and metastasis: a systematic comparison of
evidence from observational studies versus randomised trials.
Lancet Oncol. 2012;13:518–27.
41. Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-
controlled prevention trial of aspirin and/or resistant starch in
young people with familial adenomatous polyposis. Cancer Prev
Res (Phila). 2011;4:655–65.
42. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin
on cancer risk in carriers of hereditary colorectal cancer: an
analysis from the CAPP2 randomised controlled trial. Lancet.
2011;378:2081–7.
43. Barry EL, Sansbury LB, Grau MV, et al. Cyclooxygenase-2
polymorphisms, aspirin treatment, and risk for colorectal ade-
noma recurrence—data from a randomized clinical trial. Cancer
Epidemiol Biomarkers Prev. 2009;18:2726–33.
44. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant
starch on colorectal neoplasia in the Lynch syndrome. N Engl J
Med. 2008;359:2567–78.
45. Farrell B, Godwin J, Richards S, et al. The United Kingdom
Transient Ischaemic Attack (UK-TIA) aspirin trial: final results.
J Neurol Neurosurg Psychiatry. 1991;54:1044–54.
46. Vanwormer JJ, Greenlee RT, McBride PE, et al. Aspirin for
primary prevention of CVD: are the right people using it? J Fam
Pract. 2012;61:525–33.
47. Filippi A, Bianchi C, Parazzini F, et al. A national survey on
aspirin patterns of use and persistence in community outpatients
in Italy. Eur J Cardiovasc Prev Rehabil. 2011;18:695–703.
48. Sanchez DR, Diez Roux AV, Michos ED, et al. Comparison of
the racial/ethnic prevalence of regular aspirin use for the primary
prevention of coronary heart disease from the multi-ethnic study
of atherosclerosis. Am J Cardiol. 2011;107:41–6.
49. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that
prevent cardiovascular disease: meta-analysis on 376,162
patients. Am J Med. 2012;125(882–87):e1.
50. Cook NR, Cole SR, Buring JE. Aspirin in the primary prevention
of cardiovascular disease in the Women’s Health Study: effect of
noncompliance. Eur J Epidemiol. 2012;27:431–8.
132 C. Brotons et al.
51. American Diabetes Association. Standards of medical care in
diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–66.
52. Perk J, De Backer G, Gohlke H, European Guidelines on car-
diovascular disease prevention in clinical practice (version,
2012), et al. The Fifth Joint Task Force of the European Society
of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives
of nine societies and by invited experts). Eur Heart J. 2012;
2012(33):1635–701.
53. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary
prevention of cardiovascular disease: antithrombotic therapy and
prevention of thrombosis, 9th ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest.
2012;141:e637S–68S.
54. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the
primary prevention of stroke: a guideline for healthcare profes-
sionals from the American Heart Association/American Stroke
Association. Stroke. 2011;42:517–84.
55. US Preventive Services Task Force. Aspirin for the prevention of
cardiovascular disease: U.S. Preventive Services Task Force
recommendation statement. Ann Intern Med. 2009;150:396–404.
56. Farkouh ME, Fuster V. Diabetes and aspirin: beware of under-
powered negative trials. Nat Clin Pract Cardiovasc Med.
2009;6:1.
57. Patrono C. Diabetes: does aspirin increase the risk of major
bleeds? Nat Rev Cardiol. 2012;9:495–6.
58. Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet
cyclooxygenase activity explains interindividual variability in
responsiveness to low-dose aspirin in patients with and without
diabetes. J Thromb Haemost. 2012;10:1220–30.
59. Rosiak M, Postula M, Kaplon-Cieslicka A, et al. The effect of
doubling the dose of acetylsalicylic acid (ASA) on platelet
function parameters in patients with type 2 diabetes and platelet
hyperreactivity during treatment with 75 mg of ASA: a sub-
analysis of the AVOCADO study. Kardiol Pol. 2013;71:552–7.
60. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of
aspirin on colorectal cancer incidence and mortality: 20-year
follow-up of five randomised trials. Lancet. 2010;376:1741–50.
61. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use
of aspirin and nonsteroidal anti-inflammatory drugs and risk of
colorectal cancer. JAMA. 2005;294:914–23.
62. Cook NR, Lee IM, Zhang SM, et al. Alternate-day low-dose
aspirin and cancer risk: long-term observational follow-up of a
randomized trial. Ann Intern Med. 2013;159:77–85.
63. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and
harms of prophylactic use of aspirin in the general population.
Ann Oncol. 2014 (Epub ahead of print).
64. Benamouzig R, Uzzan B, Martin A, et al. Cyclooxygenase-2
expression and recurrence of colorectal adenomas: effect of
aspirin chemoprevention. Gut. 2010;59:622–9.
65. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-
selective inhibition of prostanoid formation: transducing bio-
chemical selectivity into clinical read-outs. J Clin Invest.
2001;108:7–13.
66. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention
of colorectal neoplasia: an overview. Cancer Prev Res (Phila).
2012;5:164–78.
67. Laine L. Review article: gastrointestinal bleeding with low-dose
aspirin—what’s the risk? Aliment Pharmacol Ther. 2006;24:
897–908.
68. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose
aspirin for the prevention of atherothrombosis. N Engl J Med.
2005;353:2373–83.
69. Fletcher EH, Johnston DE, Fisher CR, et al. Systematic review:
Helicobacter pylori and the risk of upper gastrointestinal bleeding
risk in patients taking aspirin. Aliment Pharmacol Ther.
2010;32:831–9.
70. Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter
pylori infection on long-term risk of peptic ulcer bleeding in low-
dose aspirin users. Gastroenterology. 2013;144:528–35.
71. Sutcliffe P, Connock M, Gurung T, et al. Aspirin in primary
prevention of cardiovascular disease and cancer: a systematic
review of the balance of evidence from reviews of randomized
trials. PLoS One. 2013;8:e81970.
72. Avivi D, Moshkowitz M, Detering E, et al. The role of low-dose
aspirin in the prevention of colorectal cancer. Expert Opin Ther
Targets. 2012;16:S51–62.
73. Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper
gastrointestinal symptoms on nonadherence to, and discontinua-
tion of, low-dose acetylsalicylic acid in patients with cardiovas-
cular risk. Am J Cardiovasc Drugs. 2010;10:281–8.
74. Eyre H, Kahn R, Robertson RM, et al. Preventing cancer, car-
diovascular disease, and diabetes: a common agenda for the
American Cancer Society, the American Diabetes Association,
and the American Heart Association. Circulation. 2004;109:
3244–55.
Aspirin in Primary Prevention 133
